Aytu bioscience, inc (AYTU)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Feb'15Dec'14Nov'14Sep'14May'14Mar'14Feb'14Nov'13Aug'13May'13Feb'13Nov'12Aug'12May'12Feb'12Nov'11Aug'11May'11Feb'11Nov'10
Product revenue, net

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue, net

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues
Product and service revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,721

1,076

635

176

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

511

85

85

85

85

76

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

14,486

8,708

7,328

7,320

6,529

4,759

4,015

3,660

3,570

3,856

3,599

3,221

3,323

3,097

2,773

2,562

1,807

1,162

721

261

92

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Cost of sales

3,629

2,247

2,166

2,202

1,794

2,314

2,174

2,050

2,159

1,346

1,512

1,417

1,402

1,418

1,111

957

710

369

125

88

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

398

428

511

589

603

609

182

167

162

327

868

959

3,594

4,458

5,503

6,127

4,109

3,659

3,141

3,219

3,655

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development - related party (Note 9)

-

-

-

-

-

-

-

-

-

-

-

387

435

191

191

191

191

191

197

203

184

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

26,060

21,927

20,457

18,887

17,914

17,183

16,690

17,732

17,519

17,267

16,356

17,442

16,833

14,613

12,659

8,517

6,445

5,350

4,412

3,980

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative - related party

0

6

98

351

351

345

253

0

27

63

114

165

190

234

269

307

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of finite-lived intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

3,474

2,678

2,259

2,136

1,957

1,770

1,619

1,553

1,594

0

0

-

0

-

-

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization and impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

33,562

27,289

25,493

24,166

22,622

24,077

22,777

23,360

24,545

22,166

22,114

23,346

31,647

29,790

28,280

24,266

11,859

9,575

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

1

-

1

1

1

3

1

1

1

0

0

0

0

0

0

0

Professional fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

31

-

27

15

18

16

17

18

17

41

42

45

44

0

0

0

Contributed services, related party (Note 3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

3

-

4

4

6

8

8

8

7

5

4

5

4

0

0

0

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

22

0

26

29

29

38

35

31

33

63

71

85

84

0

0

0

Loss from operations

-19,076

-18,581

-18,164

-16,846

-16,092

-19,318

-18,761

-19,700

-20,974

-18,310

-18,514

-20,125

-28,324

-26,692

-25,507

-21,704

-10,555

-9,134

-7,703

-7,632

-5,492

0

-3,706

0

-2,138

-55

-

-56

-48

-52

-60

-59

-56

-56

-109

-118

-135

-133

0

0

0

Other (expense) income
Other (expense), net

1,317

973

654

535

576

568

637

749

2,222

2,116

2,307

2,534

1,947

5,941

5,793

5,491

4,432

393

190

114

111

0

77

0

41

5

0

5

5

4

4

3

3

3

5

5

5

3

0

0

0

Gain from derecognition of contingent consideration

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) on investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on investment

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) on investment

-

-

-

-

-

-

-

-

-

-

-

-61

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

56

0

58

50

54

64

61

58

58

109

118

135

133

0

0

0

Other gain

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

0

-

0

-

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Gain from warrant derivative liability

-9,894

-9,896

-9,876

-9,830

2,385

5,528

6,025

6,277

3,957

834

583

212

250

261

-83

-12

-50

-78

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from warrant derivative liability

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other (expense) income

-5,931

-5,589

-10,449

-10,285

4,039

8,943

9,372

9,512

3,488

-1,574

-2,514

-2,383

-2,730

-6,420

-6,120

-6,475

-4,482

-471

-190

-114

-111

0

-77

0

-41

-5

0

-5

-5

-4

-4

-3

-3

-3

-3

-3

-2

-3

0

0

0

Net loss, before income tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-7,747

-7,594

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-23

-346

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-25,007

-24,171

-28,614

-27,131

-12,052

-10,374

-9,389

-10,187

-17,485

-19,884

-21,028

-22,508

-31,055

-33,113

-31,628

-28,180

-15,038

-9,606

-7,894

-7,723

-5,579

0

-3,759

0

-2,155

-61

0

-62

-53

-57

-64

-63

-59

-59

-113

-121

-138

-136

0

0

0

Weighted average number of common shares outstanding

35,275

17,538

15,325

13,880

9,061

6,477

1,759

1,743

592

205

120

679

546

392

244

-3,597

1,569

1,188

1,188

-20,634

7,901

-

7,901

-

7,901

-

44,652

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per common share

-0.15

-0.03

-0.32

-0.30

-0.50

-0.72

-1.96

42.45

-4.75

-17.86

-35.15

-3.12

-9.54

-12.27

-23.37

-314.34

-4.64

-2.80

-1.92

-9.36

-0.23

0.00

-0.21

0.00

-0.27

0.00

-0.04

0.00

0.00

-0.01

0.00

0.00

0.00

-0.01

0.00

0.00

0.00

-0.01

0.00

-0.01

-0.01

Basic and diluted weighted average common shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,835

-

5,754

-

5,117

-

4,917

4,916

-

4,889

4,889

4,863

-

4,837

4,789

4,762

4,513

4,215

4,098

3,489

Product Revenue
Total revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License Revenue
Total revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-